Paper Details

  1. Home
  2. Paper Details

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Author: AhmedSairah, AlousiAmin M, BassettRoland L, Bueso-RamosCarlos E, CiureaStefan O, GulbisAlison M, JabbourElias J, KhouriIssa F, KhouriMaria R, KorblingMartin, LedesmaCelina, MarinDavid, PatelKrina K, PopatUday R, SamuelsBarry I, TurturroFrancesco

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examines the use of lenalidomide for treating persistent chronic lymphocytic leukemia (CLL) after allogeneic stem cell transplantation (alloSCT). The study found that lenalidomide was associated with high toxicity and did not improve survival.
Paper Details　
Original Abstract of the Article :
In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor outcomes. In an effort to improve these outcomes, patients with persistent CLL who were 90 to 100 days beyond alloSCT with no evidence of graft-versus-h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28495642

データ提供：米国国立医学図書館（NLM）

Navigating the Complexities of Chronic Lymphocytic Leukemia

The treatment of [Chronic Lymphocytic Leukemia (CLL)] is complex, especially when the disease persists after [Allogeneic Stem Cell Transplantation (alloSCT)]. This study investigated the effectiveness of [Lenalidomide] in patients who continue to have CLL after alloSCT. The researchers found that while lenalidomide showed some promise in controlling the disease, it was associated with significant side effects, particularly [Acute GVHD]. The study highlights the need for alternative treatment strategies for persistent CLL after alloSCT. The research provides valuable insights into the complex interplay between [CLL], [alloSCT], and [GVHD].

Lenalidomide: A Promising but Complex Treatment Option for Persistent CLL

This research found that lenalidomide had limited effectiveness in patients with persistent CLL after alloSCT. While the median survival for patients receiving lenalidomide was [3.4 years], the drug was associated with a high rate of [Acute GVHD], leading to discontinuation in 62% of patients. This highlights the need for further research to develop more effective and safer treatment options for this challenging condition.

A Continual Search for Effective Treatments for Persistent CLL

This study emphasizes the need for alternative treatments for persistent CLL after alloSCT. The high rate of side effects with lenalidomide underscores the importance of exploring other therapies with better tolerability and efficacy.

Dr.Camel's Conclusion

This research is a reminder that the path to curing cancer is often fraught with obstacles. The study highlights the need for more research to find safe and effective treatments for persistent CLL. It's a challenging landscape, but one where we must continue to search for solutions.

Date :
  1. Date Completed 2018-01-25
  2. Date Revised 2020-04-10
Further Info :

Pubmed ID

28495642

DOI: Digital Object Identifier

NIHMS1575996

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.